CDS Lifesciences Group

CDS LifeSciences Group

A boutique advisory firm for your licensing, divestitures, M&A and fundraising solutions.


Our Mission -
"Focus on Science + Data and Get Deals Done for Clients”

What we do

We provide BD services with a focused approach & speed

BD Strategy
  • Pipeline competitiveness & prioritization
  • Competitive intelligence & market landscape
  • Technical assessment of program for BD readiness
  • Asset and Company Valuation
  • Website, SEO, PR and BD communication strategies
  • AI-BD: Database to search for your AI partner/vendor to enhance your capabilities across all functions e.g. R&D, Clinical, Commercial & Operations
Deal Execution
  • Deal Readiness; Pitch decks, conference & diligence support, project management, term-sheet preparation, deal comps, deal structuring, negotiations and contract closure
  • Business Development; In and Out-Licensing, M&A, Asset Divestitures & Fundraising

Why Us?

Start with Science and Finish with Business Deal

  • Team comes from the Industry - S&P 500 Lifesciences
    (Real experience & not brokers)
  • Significant buy & sell side experience, >$20B deals done
    (Knows Buyer's Mindset)
  • Hit the ground running from day 1 with lean teams - dedicated & economical business model
  • Deep & real connections with buyers esp. the big pharma players and VC's
  • Focused approach: quality & not quantity of projects and get the deal done attitude!
  • One stop shop - Trusted partner from BD strategy to deal execution

Typical Deal Process


Planning & Preparation
Planning & Preparation
  • Portfolio prioritization
  • Deal readiness check
  • Non-confidential and Confidential pitch deck
  • Overall strategy for outreach efforts
  • Conference planning
Market Contact
Market Contact
  • List of targets
  • Launch deal process
  • Gauge interest
  • Execute CDAs
  • Feedback & corrective actions
Due Diligence
Due Diligence
  • Data room
  • Q&A preparations
  • Technical & business calls
  • Cross-functional engagement


Term-Sheet & Negotiation
Term-Sheet & Negotiation
  • Valuation
  • Term sheet
  • Deal comps
Deal Execution
Deal Execution
  • Definitive contract
  • Negotiation
  • Closing
  • Funds flow

Our Team

Global and Experienced Team

Gaurav (Vik)
Gaurav (Vik)
President and CEO
Pharma / Biotech(San Diego)
  • ~15 years of buy & sell side deal making
  • $20B+ deals across multiple therapeutics e.g., oncology, inflammation & cell therapy
  • Deals include; In & Out licensing, M&A, R&D collaborations & international
Amgen
Shire
Gilead
Kite
Curate Biosciences
Precigen
Nick
Nick
Banker / Biotech(London)
 
  • >20 years experience in healthcare advisory, operating and board level roles
  • Nick's advisory career has included advising on the sale of STADA to Bain and Cinven, CareFusion to Becton Dickinson, Cascadian to Seattle Genetics
  • Significant deal experience both buy and sell side
J.P. Morgan
PWP Logo
Parion Sciences
Candesic
Esteve
Stada
Sirakoss
Concordia Healthcare

Deal Experience

Active Projects

Type of Client (Confidential)

Stage of Dev.

Technology / MOA / Business Model

Key Data and Differentiation

Oncology
(US Based)

Phase 1 - US

Small Molecule
Hippo-YAP inhibitor of GPR35 for solid tumor indications

  • Not directly targeting Hippo-YAP pathway, avoiding any class effect issues & strong PC data package
  • First-in-Class program

Oncology
(US Based)

Phase 1 - US

Cell Therapy, Autologous TILs

  • Unique approach in directly targeting subset of T-cells
  • Several PR's & SD observed across multiple solid tumors

Ophthalmology
(US Based)

Phase 2 - US

VEGF / RTKi conjugated to a nanomedicine to target retinal inflammation

  • SubQ injection at home administration, clean safety profile
  • Significant reduction (>70%) in VEGF / IVT injections
  • Broad indication application; wet-AMD, DME & RVO

Cell Therapy
(US Based)

Commercial Stage

CT manufacturing platform - microfluidics approach for gene editing

  • Rapid manufacturing with no virus
  • Validated and tested by industry and academia
  • A safer complex editing capability (sequential workflow) leads to fewer translocations & negative cell outcomes

MENA Distributor
(Middle-East & North Africa)

Multiple Programs

Collaborate with Co's across therapeutics for distribution rights to MENA markets

  • Established footprint and experience in MENA markets
  • Already selling commercial products for big pharma
  • Unique and dedicated sales and marketing channels

Oncology
(China)

Ph 1/2 - China

ADC - Antibody Drug Conjugate, Multiple Targets

  • Significant efficacy improvement seen across various solid tumor indications
  • Better safety profile with no ILD’s across indications
  • Currently negotiating and signed several term sheets for clients
  • Deal structure; straight out-licensing, option to acquire asset rights / M&A, and/or equity investments
  • Typical deal terms; e.g. upfront ~$10-$45M and total deal package ~$500M to $875M plus tiered royalties on commercial sales

Selected Deals and from Corporate Experience

Gilead
M & A
FortySeven
Oncology
$4.9B
2020
Gilead
M & A
celldesignlabs
Cell Therapy
$567M
2017
Amgen
M & A
onyx
Oncology
$10.4B
2013
Amgen
M & A
Decode Genetics
Platform
$415M
2012
Gilead
R&D Collab.
Tango
Oncology
~$200M / $6B+
2018 & 2020
Gilead
R&D Collab.
nurix
Oncology
~$45M / $2B+
2019
Gilead
R&D Collab.
insitro
AI/ML (Nash)
Upfront & Milestones
Gilead
R&D Collab.
Second Genome
Microbiome
Inflammation
$38M / ~$1.5B
Shire
Licensing
parion sciences
Dry Eye
$20M / $535M
2017

Get in touch

Talk to us about what your organisation wants to achieve.